TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos Fava.

Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3 years. However, beyond such term, we had no valid information.

Highlights TCT 2019

Researchers analyzed the 5-year follow-up results for the EXCEL trial, which randomized 948 patients with an intermediate or low SYNTAX score to undergo angioplasty with an everolimus-eluting stent (XIENCE, Abbott Vascular) while others were randomized to coronary artery revascularization surgery.

The primary endpoint at 5 years consisted of death, stroke, or infarction, while the secondary endpoint at 5 years was a composite of death, stroke, infarction, and ischemia-driven revascularization.

Groups were similar: the mean age was 66 years old, most patients were male, and 30% of subjects had diabetes. The SYNTAX score was 20.6 ± 6.2 for local sites and 26.5 ± 6.3 for core lab with angiography. About 80.5% of patients had severe bifurcation lesion in the left main coronary artery.


Read also: TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS.


Over 90% of patients in both groups completed the 5-year follow-up. There were no differences in the primary endpoint (22% for angioplasty and 19.2% for myocardial revascularization surgery; p = 0.13). The secondary endpoint favored myocardial revascularization surgery (24.1% vs. 31.2%; p = 0.002), driven by a higher need for ischemia-driven revascularization (16.9% vs. 10%; p > 0.001). There were no differences as regards cardiac death, infarction, or stroke. Non-cardiac death rates were higher in the angioplasty group.

Conclusion

In patients with unprotected left main coronary artery disease who had intermediate or low anatomical complexity, there were no differences between angioplasty and myocardial revascularization surgery as regards death, stroke, or infarction after a 5-year follow-up.

Courtesy of Dr. Carlos Fava.

Link to the SBHCI Publication HERE

excel

excel-5yearpdf

Original Title: EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease.

Author of the Original Title: Gregg W. Stone.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...